Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 79-84

  Katsaros, Katharina M ^a   Kastl, Stefan P ^a   Huber, Kurt ^b   Zorn, Gerlinde ^a   Maurer, Gerald ^a   Glogar, Dietmar ^a   Wojta, Johann ^a   Christ, Günter ^a   Speidl, Walter S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Wilhelminenhospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING HABIT; STABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 54049152742     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.04.017     Document Type: Article

References (26)

1. Renckens R., Roelofs J.J., de Waard V., Florquin S., Lijnen H.R., Carmeliet P., et al. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost. 3 (2005) 1018-1025
2. Sardella G, Mariani P, D'Alessandro M, De Luca L, Pierro M, Mancone M, et al., Early elevation of interleukin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res. 117:659-64.
3. Ramadan M.M., Kodama M., Mitsuma W., Ito M., Kashimura T., Ikrar T., et al. Impact of percutaneous coronary intervention on the levels of interleukin-6 and C-reactive protein in the coronary circulation of subjects with coronary artery disease. Am J Cardiol. 98 (2006) 915-917
4. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 46 (2005) 1820-1826
5. Christ G., Nikfardjam M., Huber-Beckmann R., Gottsauner-Wolf M., Glogar D., Binder B.R., et al. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication. J Thromb Haemost. 3 (2005) 233-239
6. DeYoung M.B., Tom C., and Dichek D.A. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation. 104 (2001) 1971-1972
7. Ishiwata S., Tukada T., Nakanishi S., Nishiyama S., and Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J. 133 (1997) 387-392
8. Gottsauner-Wolf M., Sochor H., Hornykewycz S., Beckmann R., Lang I., Probst P., et al. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients. Thromb Haemost. 81 (1999) 522-526
9. Konkle B.A., Schick P.K., He X., Liu R.J., and Mazur E.M. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb. 13 (1993) 669-674
10. Brogren H., Karlsson L., Andersson M., Wang L., Erlinge D., and Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood. 104 (2004) 3943-3948
11. Kastl S.P., Speidl W.S., Kaun C., Rega G., Assadian A., Weiss T.W., et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost. 4 (2006) 1790-1797
12. Christ G., Hufnagl P., Kaun C., Mundigler G., Laufer G., Huber K., et al. Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo. Arterioscler Thromb Vasc Biol 17 (1997) 723-730
13. Sawdey M., Podor T.J., and Loskutoff D.J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 264 (1989) 10396-10401
14. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., and Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 135 (2002) 284-292
15. Sawa H., Lundgren C., Sobel B.E., and Fujii S. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis. J Am Coll Cardiol. 24 (1994) 1742-1748
16. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 340 (1999) 448-454
17. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 12 (2007) 2957-2966
18. Seki T., Healy A.M., Fletcher D.S., Noguchi T., and Gelehrter T.D. IL-1beta mediates induction of hepatic type 1 plasminogen activator inhibitor in response to local tissue injury. Am J Physiol. 277 (1999) G801-809
19. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 180 (1994) 1243-1250
20. Hochholzer W., Trenk D., Frundi D., Blanke P., Fischer B., Andris K., et al. Time dependence of platelet inhibition after a 600-mg loading dose. of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
21. Jagroop I.A., Matsagas M.I., Geroulakos G., and Mikhailidis D.P. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets. 15 (2004) 117-125
22. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 358 (2001) 527-533
23. Chan A.W., Moliterno D.J., Berger P.B., Stone G.W., DiBattiste P.M., Yakubov S.L., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol. 42 (2003) 1188-1195
24. Szük T., Gyöngyösi M., Homorodi N., Kristof E., Kiraly C., Edes I.F., et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J. 153 (2007) 289-295
25. Morley J.J., and Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 389 (1982) 406-418
26. Vivekananthan D.P., Bhatt D.L., Chew D.P., Zidar F.J., Chan A.W., Moliterno D.J., et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 94 (2004) 358-360